XenoGesis and Sygnature Discovery teamed up to host the March DMDG meeting on predictive toxicology in discovery DMPK.
The event, which was held at BioCity’s new state-of-the-art Discovery Building in Nottingham was oversubscribed, with over 70 people attending.
The event was vibrant from the welcoming coffee break through to the final networking at the prosecco reception. New and old colleagues interacted and each of the talks stimulated lots of questions.
Professor Ruth Roberts, Founder of ApconiX and Professor at the University of Birmingham opened the event as the keynote speaker. Her talk covered the importance of evaluating toxicity in the discovery phase of drug development. Ruth stimulated a positive discussion by questioning whether a new chemical entity could proceed through to CTA without being tested in vivo.
The morning session of ‘Poster Flash Presentations’ provided an excellent and succinct forum for three short presentations from Melanie Sakatis (GSK), Roelof de Wilde (SOLVO) and Shaheda Ahmend (Newcastle University). These presentations focused more on experimental techniques and applications to toxicology studies.
The morning session was concluded by complementary presentations by Dominic Williams (AstraZeneca) and Manfred Ismair (XenoGesis) focusing on predictive hepatic safety models for risk injury and the role of transporters in drug-induced liver injury.
Sygnature Discovery opened the afternoon talks with a presentation by Filipa Antunes on assessing Cinchophen and Fialuridine drug induced liver injury mechanisms. Professor Gareth Jenkins of the University of Swansea then explored the interplay between genotoxic and non-genotoxic carcinogens. He outlined the impact of non-genotoxic carcinogens on the cell cycle and questioned the design of experiments for evaluating chronic exposure.
Guy Webber of Envigo gave a highly comprehensive talk on the Metabolites in Safety Testing (MIST) guidelines and explored the area of human specific metabolism. Mike Morton was the second presenter from ApconiX and updated the meeting on the changing face of cardiovascular safety testing. His evaluation on cardiomyocyte derived spheroids in safety testing picked up on a theme which had arisen throughout the day on the movement within the field from 2-D cell cultures systems to 3-D cell culture systems for evaluating toxicity in the discovery phase.
Toby Athersuch (Imperial College) closed the day’s proceedings in exploring metabolic differences in pigs and the views of the use of mini-pig as a non-rodent toxicology species.
For more information on DMDG, please click here.